Afatinib alone and in combination with vinorelbine or paclitaxel, in patients with HER2-positive breast cancer who failed or progressed on prior trastuzumab and/or lapatinib (LUX-Breast 2): an open-label, multicenter, phase II trial

PURPOSE: Resistance to HER2 (ErbB2)-targeted therapy may be mediated by other members of the ErbB family. We investigated the efficacy and safety of the irreversible ErbB family blocker, afatinib, alone as first-line therapy in the advanced setting and in combination with vinorelbine or paclitaxel f...

Descripción completa

Detalles Bibliográficos
Autores principales: Hickish, Tamas, Mehta, Ajay, Liu, Mei-Ching, Huang, Chiun-Sheng, Arora, Rajendra Singh, Chang, Yuan-Ching, Yang, Youngsen, Vladimirov, Vladimir, Jain, Minish, Tsang, Janice, Pemberton, Karine, Sadrolhefazi, Behbood, Jin, Xidong, Tseng, Ling-Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8960620/
https://www.ncbi.nlm.nih.gov/pubmed/35138529
http://dx.doi.org/10.1007/s10549-021-06449-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8960620/
https://www.ncbi.nlm.nih.gov/pubmed/35138529
http://dx.doi.org/10.1007/s10549-021-06449-4

Ejemplares similares